quinazolines has been researched along with osi-420 in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, SD; He, P; Hidalgo, M; Rudek, MA; Zhao, M | 1 |
| Chen, EX; Moore, MJ; Siu, LL; Zhang, W | 1 |
| Eppler, S; Frohna, P; Hamilton, M; Kenkare-Mitra, SR; Ling, J; Lu, J; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Beard, SE; Cagnoni, PJ; Clark, GM; Hamilton, M; Rusk, J; Witt, K; Wolf, JL | 1 |
| Jones, DR; Masters, AR; Sweeney, CJ | 1 |
| Bai, F; Broniscer, A; Fraga, C; Gajjar, A; Krasin, MJ; O'Shaughnessy, M; Panetta, JC; Stewart, CF | 1 |
| Balis, FM; Fox, E; McCully, C; Meany, HJ; Tucker, C | 1 |
| Conklin, E; Dwyer-Nield, LD; Eckhardt, SG; Fritz, JM; Gustafson, DL; Iwata, KK; Kane, S; Malkinson, AM; Redente, EF; Shroyer, RJ; Tucker, C; Zerbe, LK | 1 |
| Fettner, S; Ling, J; Lum, BL; Rakhit, A; Riek, M | 1 |
| Baker, SD; Figg, WD; Gonzalez, FJ; Harris, JW; Smith, NF; Sparreboom, A | 1 |
| Benlyazid, A; Chatelut, E; Delord, JP; Hennebelle, I; Lefebvre, JL; Malard, L; Rochaix, P; Sarini, J; Thomas, F; White-Koning, M | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Bai, F; Carcaboso, AM; Elmeliegy, MA; Stewart, CF; Tagen, M | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Fukudo, M; Ikemi, Y; Inui, K; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Terada, T; Teramukai, S; Togashi, Y | 1 |
| Gréen, H; Lundeberg, J; Svedberg, A; Vikingsson, S; Vikström, A | 1 |
| Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T | 1 |
| Ang, MK; Chowbay, B; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Toh, CK; Zhang, Z | 1 |
| Bulitta, JB; Jeong, SW; Joo, SH; Kim, S; Kim, TH; Kwon, DR; Lee, DY; Ma, E; Park, GY; Shin, BS; Shin, S; Weon, KY; Yoo, SD | 1 |
| Barasa, L; Gupta, V; Kulkarni, NS; Muth, A; Parvathaneni, V; Perron, JC; Shukla, SK; Yoganathan, S | 1 |
| Beijnen, JH; Rood, JJM; Somovilla, VJ; Sparidans, RW; Toraño, JS | 1 |
8 trial(s) available for quinazolines and osi-420
| Article | Year |
|---|---|
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cross-Over Studies; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Therapeutic Equivalency | 2006 |
Effects of smoking on the pharmacokinetics of erlotinib.
Topics: Adult; Area Under Curve; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Molecular Structure; Quinazolines; Reference Values; Safety; Smoking; Time Factors | 2006 |
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
Topics: Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Child; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Quinazolines | 2007 |
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
Topics: Administration, Oral; Adult; Aged; Algorithms; Area Under Curve; Creatine Kinase; Cross-Over Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fasting; Food-Drug Interactions; gamma-Glutamyltransferase; Glossitis; Hematuria; Humans; Liver; Male; Middle Aged; Molecular Structure; Patient Dropouts; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2008 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
15 other study(ies) available for quinazolines and osi-420
| Article | Year |
|---|---|
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Topics: Calibration; Chromatography, Liquid; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2003 |
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.
Topics: Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Humans; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2005 |
The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Erlotinib Hydrochloride; Humans; Molecular Structure; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Topics: Animals; Area Under Curve; Erlotinib Hydrochloride; Injections, Intravenous; Macaca mulatta; Male; Metabolic Clearance Rate; Quinazolines | 2008 |
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sex Factors | 2008 |
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Erlotinib Hydrochloride; Esters; Female; Mice; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Spiro Compounds | 2008 |
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2009 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.
Topics: Animals; ATP-Binding Cassette Transporters; Carrier Proteins; Cell Line; Central Nervous System; Erlotinib Hydrochloride; Extracellular Fluid; Female; Humans; Mice; Mice, Knockout; Quinazolines; Solubility; Tissue Distribution | 2011 |
A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Topics: Calibration; Chromatography, Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Microsomes, Liver; Plasma; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2015 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir | 2015 |
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Biotransformation; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Gemcitabine; Male; Plant Extracts; Plants, Medicinal; Protective Agents; Quinazolines; Rats; Rats, Sprague-Dawley | 2017 |
Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; Drug Liberation; Esterases; Humans; Lung Neoplasms; Lysosomes; Protein Kinase Inhibitors; Quantum Dots; Quinazolines | 2019 |
Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification.
Topics: Chromatography, Liquid; Erlotinib Hydrochloride; Isomerism; Linear Models; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2021 |